Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF‑7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED50 for this effect is 0.05-0.15 µg/mL in the presence of 14 ng/mL Recombinant Human IGF‑II (Catalog # 292-G2).
Source
Mouse myeloma cell line, NS0-derived human IGFBP-3 protein Gly28-Lys291, with an N-terminal Met
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.
Applications/Dilutions
Dilutions
Bioactivity
Theoretical MW
29 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
37-47 kDa, reducing conditions
Publications
Read Publications using 675-B3 in the following applications:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human IGFBP-3 Protein, CF
acid stable subunit of the 140 K IGF complex
binding protein 29
binding protein 53
growth hormone-dependent binding protein
IBP-3
IBP3BP-53
IGF-binding protein 3
IGFBP3
IGFBP-3
insulin-like growth factor binding protein 3
insulin-like growth factor-binding protein 3
Background
Insulin-like growth factor binding protein-3 (IGFBP-3) is one of six members of the insulinlike growth factor (IGF) binding protein superfamily which function to modulate the biological activity of IGF (1). Human IGFBP-3 is the major binding protein of IGF where it exists in circulation as a ternary complex with the acid-labile subunit (ALS) (2). Like other IGFBP members, human IGFBP-3 includes a cysteine-rich C-terminal domain, a highly variable central linker domain, and another N-terminal cysteine-rich domain (2, 3). Human IGFBP-3 cDNA encodes a 291 amino acid (aa) precursor protein with a 27 aa signal peptide that is processed to generate the 264 aa mature protein. Mature human IGFBP-3 shares 82% aa sequence identity with both mouse and rat IGFBP-3. Post-translational glycosylation and phosphorylation of IGFBP-3 modifies the affinities of the binding protein. Proteolysis of IGFBP-3 by tissue plasminogen activator (tPA), a disintegrin and metaloproteases (ADAMs), and prostate specific antigen (PSA) contributes to IGFBP-3 degradation or a reduction in its affinity for IGF (4-6). The majority of soluble IGFBP-3 found in circulation is secreted from hepatic non-parenchymal cells. IGFBP-3 expression can be modulated by p53 as well as by various cytokines and growth factors (7, 8). In addition to its role in stabilizing and transporting circulating IGF, IGFBP-3 has been shown to potentiate EGF-EGFR-mediated cell growth through the activation of sphingosine kinase1 (SPHK1) and sphingosin-1-phosphate (S1P) (9, 10). IGFBP-3 has also been shown to modulate adipogenesis (11). Binding of IGFBP-3 to non-IGF-related ligands has been shown to regulate TGF-beta signaling, DNA damage, apoptosis, autophagy, and gene transcription (12). Interactions with non-IGF-related ligands is thought to contribute, in part, to the dichotomous stimulatory and inhibitory effects of IGFBP-3 on cell growth (2).
Shimasaki, S. and N. Ling (1991) Prog. Growth Factor Res. 3:243.
Baxter, R.C. (2013) J. Cell Commun. Signal 7:179.
Baxter, R.C. (2014) Nat. Rev. Cancer 14:329.
Mochizuki, S. et al. (2004) Biochem. Biophys. Res. Commun. 315:79.
Cohen, P. et al. (1994) J. Endocrinol. 142:407.
Bang, P. (1995) Prog. Growth Factor Res. 6:285.
Perks, C.M. and J.M. Holly (2008) J. Mammary Gland Biol. Neoplasia 13:455.
Chan, K. and E.M. Spencer (1997) Endocrine 7:95.
Guix, M. et al. (2008) J. Clin. Invest. 118:2609.
Martin, J.L. et al. (2009) J. Biol. Chem. 284:25542.
Chan, S.S. et al. (2009) Am. J. Physiol. Endocrinol. Metab. 296:E654.
Martin, J.L. and R.C. Baxter (2011) Growth Factors 29:235.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our Recombinant Human IGFBP-3 Protein, CF and receive a gift card or discount.